Description

BSE lists 4,477,612 new equity shares of Suven Life Sciences Ltd issued on preferential basis pursuant to conversion of warrants, effective February 26, 2026.

Summary

BSE has listed 4,477,612 new equity shares of Suven Life Sciences Ltd (Scrip Code: 530239) effective Thursday, February 26, 2026. These shares were issued on a preferential basis to Non-Promoters pursuant to the conversion of warrants at an issue price of Rs. 134.00 per share (face value Rs. 1.00 + premium of Rs. 133.00).

Key Points

  • Scrip Code: 530239 (Suven Life Sciences Ltd)
  • Number of Shares Listed: 4,477,612 equity shares
  • Face Value: Rs. 1.00 per share
  • Issue Price: Rs. 134.00 per share (Rs. 133.00 premium)
  • Allottees: Non-Promoters (preferential basis)
  • Basis of Issue: Conversion of warrants
  • Distinctive Numbers: 227474208 to 231951819
  • ISIN: INE495B01038
  • Pari-passu: Shares rank pari-passu with existing equity shares
  • Effective Trading Date: February 26, 2026

Regulatory Changes

No new regulatory changes introduced. This circular is a standard listing notification under BSE’s listing framework for preferential allotments resulting from warrant conversions.

Compliance Requirements

  • Trading members are informed to note the listing and permit trading of the new securities from February 26, 2026.
  • All 4,477,612 shares are subject to a lock-in period and cannot be traded until August 30, 2026.

Important Dates

  • Date of Allotment: January 29, 2026
  • Effective Listing / Trading Date: February 26, 2026
  • Lock-in Expiry Date: August 30, 2026

Impact Assessment

The listing adds 4,477,612 shares to the tradeable equity base of Suven Life Sciences Ltd; however, since all newly listed shares are locked in until August 30, 2026, there is no immediate increase in free-float. Market impact is expected to be limited in the near term. Post lock-in expiry, the additional supply could exert modest downward pressure on the stock price depending on market conditions at that time.

Impact Justification

Routine preferential allotment listing following warrant conversion for a mid-cap pharma company; shares are subject to lock-in until August 2026, limiting immediate market impact.